Search

Your search keyword '"Elizabeth, Nazarian"' showing total 2 results
Start Over Author "Elizabeth, Nazarian" Journal antimicrobial agents and chemotherapy
2 results on '"Elizabeth, Nazarian"'

1. Characterization of the First Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate Harboring bla SIM-1 from the United States

Author

Utpala Bandy, Navjot Singh, Catharine Prussing, Maria Karlsson, Kimberlee A. Musser, Richard C Huard, Ewa King, Patricia McAuley, Theresa Canulla, Elizabeth Nazarian, María-José Machado, and Michael Gosciminski

Subjects
Pharmacology, business.industry, Pseudomonas aeruginosa, Transmission (medicine), biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, Antimicrobial, medicine.disease_cause, Microbiology, Infectious Diseases, Antibiotic resistance, polycyclic compounds, Carbapenem resistant Pseudomonas aeruginosa, bacteria, Medicine, Pharmacology (medical), business
Abstract

The emergence and transmission of metallo-β-lactamases are significant public health concerns that threaten the utility of antimicrobial therapy (1, 2).….

Published
2021
Full Text
View/download PDF

2. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Author

Janine Bodnar, Jennifer Y Huang, Nadine Peinovich, Stephanie Gumbis, Justin Simpson, Allen Bateman, Bradley Craft, Sandra Boyd, Joseph D. Lutgring, David Lonsway, Christine Wagner, Paula Snippes Vagnone, Victoria N Stone, Sarah Sabour, Maria Karlsson, Danielle Lower, Allison C Brown, Elizabeth Nazarian, Michelle Therrien, and Amelia Bhatnagar

Subjects
Susceptibility testing, antibiotic resistance, carbapenemases, medicine.medical_treatment, Avibactam, MBL, Microbial Sensitivity Tests, Aztreonam, Ceftazidime, beta-Lactamases, Microbiology, 03 medical and health sciences, chemistry.chemical_compound, Enterobacterales, 0302 clinical medicine, Antibiotic resistance, polycyclic compounds, Humans, Medicine, Pharmacology (medical), 030212 general & internal medicine, Pharmacology, 0303 health sciences, 030306 microbiology, business.industry, Broth microdilution, Drug Resistance, Microbial, susceptibility testing, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, antimicrobial combinations, Anti-Bacterial Agents, Drug Combinations, Infectious Diseases, chemistry, Susceptibility, Beta-lactamase, bacteria, aztreonam-avibactam, Laboratories, business, Azabicyclo Compounds
Abstract

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC50 and MIC90 values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results